pharma · Moderately to Severely Active Rheumatologic Disease · Moderately to Severely Active Ulcerative Colitis · SYRE
Spyre Therapeutics
Spyre Therapeutics patent portfolio — 0 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Company details
- Status
- Public
- HQ
- Waltham, USA
- Founded
- 2023
- Employees
- 110
- Programs
- 8
- Drugs
- 1
- Patents
- 0
Spyre Therapeutics patents
0 pharmaceutical patents indexed for Spyre Therapeutics. 0 expire within 24 months.
Spyre Therapeutics has 0 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
No patents matched
Frequently asked questions
How many patents does Spyre Therapeutics have?
0 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do Spyre Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.